To further elucidate the role of Nrf2 in NSCLC tumorigenesis, we identified PRDX5 (Peroxiredoxin 5) as a novel binding partner for Nrf2 through immunoprecipitation in tissues and lung cancer cells. Here, PRDX5 is linked to lung carcinoma.